Surveillance for Gastric Intestinal Metaplasia
Most patients with gastric intestinal metaplasia (GIM) do NOT require routine endoscopic surveillance, but high-risk patients should undergo surveillance endoscopy every 3 years.
Risk Stratification: Who Needs Surveillance?
The decision to pursue surveillance hinges on identifying high-risk features. Surveillance is recommended for patients with ANY of the following high-risk characteristics 1, 2:
Endoscopic High-Risk Features:
- Extensive GIM: Corpus-extended changes (Kimura-Takemoto C3+ or EGGIM 5+)
- Endoscopically visible extensive atrophic changes
Histologic High-Risk Features:
- Advanced histological staging: OLGA/OLGIM stages III or IV
- Severe atrophic changes involving both antrum AND corpus
- Incomplete (Type II or III) intestinal metaplasia (vs. complete Type I)
- Any grade of dysplasia
Patient-Specific High-Risk Features:
- First-degree family history of gastric cancer
- Racial/ethnic minorities at increased risk (Asian, Hispanic, Black, Native American populations)
- Immigrants from high gastric cancer incidence regions (East Asia, Eastern Europe, Central/South America)
- Persistent/refractory H. pylori infection despite treatment attempts
Who Does NOT Need Surveillance?
No surveillance is recommended for 3, 1, 2:
- Mild to moderate atrophy or GIM restricted to the antrum only
- Complete (Type I) intestinal metaplasia without other risk factors
- Absence of family history and no high-risk demographic features
- This constitutes the majority of patients with incidentally detected GIM
Surveillance Intervals
Standard High-Risk Surveillance:
Every 3 years with high-quality endoscopy for patients meeting high-risk criteria 1, 2
Special Circumstances:
Within 1 year for risk re-stratification if 3:
- Concerns about completeness of baseline endoscopy
- Newly diagnosed high-risk features requiring confirmation
- Shared decision-making favors early reassessment
Within 3-6 months if dysplasia is found 1, 4:
- High-grade dysplasia with incomplete resection: 3 months
- Low-grade dysplasia with incomplete resection: 6 months
- After complete resection: 6 months (high-grade) or 1 year (low-grade)
When to Stop Surveillance:
Discontinue surveillance at age 80 or when significant comorbidities preclude treatment of detected lesions 1
Essential Management Components
H. pylori Testing and Eradication:
All patients with GIM must be tested for H. pylori and treated if positive 3, 1, 2. This is the single most important non-endoscopic intervention, as eradication reduces progression risk to dysplasia and cancer.
High-Quality Endoscopy Requirements:
When surveillance is performed 1, 2:
- Minimum 7 minutes of careful mucosal inspection
- Virtual chromoendoscopy (narrow-band imaging or similar) to guide biopsies
- Systematic biopsy protocol: Minimum 2 biopsies from antrum AND 2 from corpus, in separate labeled vials
- Additional targeted biopsies of any suspicious lesions
- Photo-documentation of findings
Critical Pitfalls to Avoid
Do not perform routine surveillance on low-risk GIM: The 2020 AGA guidelines explicitly recommend AGAINST routine surveillance for most GIM patients 3. This represents the majority of cases.
Do not repeat short-interval endoscopy for risk stratification unless specific high-risk features warrant it 3. The evidence does not support this practice.
Do not rely on white-light endoscopy alone: Virtual chromoendoscopy significantly improves detection of dysplasia and proper staging 1, 2.
Do not forget geographic/ethnic risk factors: A patient from Korea, Japan, or Peru with even limited GIM may warrant surveillance despite "low-risk" histology 2.
Reconciling Guideline Differences
The most recent 2025 MAPS III European guidelines 1 and 2025 ACG guidelines 2 align closely with each other and supersede the more conservative 2020 AGA guidelines 3. The newer guidelines provide more specific risk stratification criteria and consistently recommend 3-year intervals for high-risk patients. The 2024 Gut review 5 confirms international consensus is converging toward this risk-stratified approach.
The key paradigm shift: Moving from "surveillance for all GIM" to "surveillance only for high-risk GIM," which better balances cancer prevention against the burdens and costs of unnecessary endoscopy in the vast majority of low-risk patients.